Observational
Observational Model: Cohort, Time Perspective: Prospective
Prospectively validate the use of gene expression profiling (GEP) for the risk-stratification and classification of MM
All patients will have additional bone marrow taken for GEP studies after informed consent at entry into the treatment protocol. CD138 positive cells will be selected using magnetic beads and RNA extracted. The quality of RNA will be checked using the Agilent Bioanalyzer. GEP will be performed using Affymetrix U133plus2.0 chip.
Singapore: Domain Specific Review Boards
2012/00058
NCT01619358
March 2012
Name | Location |
---|